Author:
Parra H S,Cavina R,Latteri F,Zucali P A,Campagnoli E,Morenghi E,Grimaldi G C,Roncalli M,Santoro A
Publisher
Springer Science and Business Media LLC
Reference22 articles.
1. Arteaga CL (2002) Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 7(Suppl 4): 31–39
2. Bailey LR, Kris M, Wolf M, Kay A, Averbuch S, Askaa J, Janas M, Schmidt K, Fukuoka M (2003) Tumor EGFR membrane staining is not clinically relevant for predicting response in patients receiving gefitinib (‘Iressa’, ZD1839) monotherapy for pretreated advanced non-small-cell lung cancer: IDEAL 1 and 2. Poster Presented at the AACR, Washington, DC, USA, July 11–14, Poster number LB-170
3. Brundage MD, Davies D, Mackillop WJ (2002) Prognostic factors in non-small cell lung cancer. A decade of progress. Chest 122: 1037–1057
4. Ciardiello F, Tortora G (2003) Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. Eur J Cancer 39: 1348–1354
5. Forsythe B, Faulkner K (2003) Safety and tolerability of gefitinib (‘Iressa’, ZD1839) in advanced NSCLC: overview of clinical experience. Poster Presented at the ERS, Vienna, Austria, September 27–October 1, Poster number P327
Cited by
182 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献